Vopimetostat not checked
Tango Therapeutics, Inc. · TNG462
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TNG462, a selective PRMT5 inhibitor, will be administered orally”In the company’s words, NCT05732831 on ClinicalTrials.gov
- Tested for
- PDAC (2 trials), PDAC - Pancreatic Ductal Adenocarcinoma (2 trials), NSCLC (2 trials), RAS Mutation (2 trials), MTAP Deletion (2 trials), Lung Cancer (2 trials), Pancreatic Cancer Metastatic (2 trials), Thoracic Cancer (2 trials) and 2 more
- Main trialPhase 1/2
- “This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.”In the company’s words, NCT06188702 on ClinicalTrials.gov
- Other names
- TNG462
Other drugs for PDAC
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up4
- 1 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Nov 2031Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 1 May 2027 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | |
| Phase 1/2Recruiting | Jun 2027 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | |
| Phase 1/2Recruiting | Jun 2027 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | |
| Phase 1/2Not yet recruiting | Nov 2031 | TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026